File(s) under permanent embargo
Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM
Methods: We reviewed 35 patients seropositive for GM1 (monosialo-asialo [immunoglobulin M, IgM; immunoglobulin G, IgG]) and/or GD1b (disialo [IgG, IgM]) autoantibodies having MMN, classic CIDP, or MADSAM. Immune-treatment responsiveness and clinical course was compared with antibody negative disease controls.
Results: Seventy-nine percent of seropositives with an initial diagnosis of MMN were immunotherapy responsive compared with 46% of seronegatives (P = 0.045). Eight ganglioside antibody positive MMN patients of 19 (42%) developed sensory findings consistent with MADSAM compared with 3 of 41 (7%) seronegative MMN patients (P = 0.003). MMN and MADSAM patients with ganglioside antibody positivity had more sustained treatment responses (P = 0.03).
Discussion: Patients initially diagnosed with MMN seropositive for diverse GM1 autoantibodies appear more likely to have sustained treatment response and evolution to MADSAM.
History
Publication title
Muscle and NerveVolume
57Issue
6Pagination
1000-1005ISSN
0148-639XDepartment/School
Menzies Institute for Medical ResearchPublisher
John Wiley & Sons IncPlace of publication
111 River St, Hoboken, USA, Nj, 07030Rights statement
Copyright 2017 Wiley Periodicals, Inc.Repository Status
- Restricted